News and Comments

ARIAD: ICLUSIG'S APPROVAL DESERVES HONORING THE DEVELOPER, NOT BASHING ITS STOCK

  Monday, December 17, 2012

On Friday, December 14, the FDA granted early and accelerated approval of Ariad’s (ARIA) further reaching tyrosine kinase inhibitor Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy. More...

ImmunoGen's Press Release Is More Than Mere News

  Tuesday, December 04, 2012

Give me the money or the hope of having it; you will see what I can do with my Targeted Antibody Payload (TAP) technology and my proprietary antibodies. That’s the message we feel ImmunoGen (IMGN) has meant to send about its upcoming clinical data presentations at the 54th annual meeting of the American Society of Hematology (ASH) to be held December 8-11, 2012 in Atlanta, GA. More...

THE ROAD TOWARDS FAR-REACHING THERAPEUTICS THROUGH ILMN, SRPT AND EXEL.

  Monday, December 03, 2012

ILLUMINA (ILMN): Illumina is approaching its 52week high. We remind that around June/July 2011  the stock had reached for over $75 to be badly hit because of fear of the bad economy and dwarfing of the healthcare budget, which was relevant. The stock had reached as low as the mid-twenties. At the time we believed this price was an invitation to buy the stock. As a matter of fact ILMN  jumped overnight from around $30 to over $50 following Roche’s offer to buy the firm.       More...

ALZHEIMER'S DISEASE BETWEEN THE BETA AMYLOID AND THE TAU. COULD BOTH THEORIES BE TRUE?

  Tuesday, November 13, 2012

Many are asking our opinion on the Wall Street Journal’s article on Alzheimer’s Disease. To begin with, we would like to state that we do not believe that the beta amyloid hypothesis has failed with regard to Alzheimer’s Disease (AD), but that clearing the plaques has failed because the treatments were given after the disease has reached the stage of no return, i.e., when  the nerve cells could not be resurrected. That’s why there are still fervent believers in the beta amyloid theory who say that beta amyloid needs to be attacked very early in the disease cycle—perhaps before symptoms begin—for such medicines to work.    More...

IMMUNOGEN TAP TECHNOLOGY: UNPARALLELED IN BREADING SAFER AND MOST EFFECTIVE CANCER DRUGS

  Friday, November 02, 2012

Before we comment on what some ImmunoGen’s (IMGN) shareholders’ believe was a staged, premeditated assault on the firm during the question and answer segment of the firm’s financial conference call, we decided to revisit with the recorded session. ImmunoGen reminded its shareholders and the analysts about the advantages of its conjugated monoclonal antibody Trastuzumab emtansin (T-DM1) over the use of (Herceptin alone in all HER2+ metastatic breast cancer patients. Various trial results demonstrated T-DM1 significantly improved both overall survival and progression-free survival of HER2+ metastatic breast cancer patients with fewer adverse events than Herceptin. These results were the basis of the NDA submitted to the FDA and the European Medicinal Agency in August 2012. More...

CHEMOCENTRIX (CCXI): A LEADER OF A NEW LINE OF INVESTIGATIONAL TREATMENTS

  Monday, October 08, 2012

In an effort to find additional small biotech firms with solid scientific fundamentals and products that promise reaching beyond the limiting horizon, we pinpointed ten to date. We picked them from among one hundred biotech firms that have little, or none of the properties that make out   super achievers. We decided to go on and start with a company called ChemoCentryx (CCXI). Our selection was not based on priority, preference, or any other reason that might insinuate advantages over the other nine firms we picked for comprehensive reviewing. It was rather based on curiosity triggered by a recent announcement by the firm of preclinical results of a small molecule oral drug CCX872 aimed at blocking the chemokine receptor CCR2 for the treatment of diabetes nephropathy.  More...

A PRESS RELEASE ABOUT POSSIBLE EXISTING CURE FOR ALZHEIMER'S DISEASE CANNOT BE OVERLOOKED

  Wednesday, September 26, 2012

CSHL Scientists Use Cancer Drugs to Reverse Alzheimer's-Like Memory Loss More...

BIOTECHNOLOGY: ON THE WAY TO MEETING HIGHLY AMBITIOUS EXPECTATIONS

  Wednesday, September 05, 2012

 More...

IMMUNOGEN: TWO GOOD NEWS IN ONE ANNOUNCEMENT

  Monday, August 27, 2012

Targeted Antibody Payload (TAP) technology did not lie and we knew it and had never been skeptical about the fact that it is a superior technology for cancer treatment. Indeed, ImmunoGen’s (IMGN) lead TAP drug, trastuzumab emtansine for HER2 breast cancer continued to show its superiority over other cancer drugs and other delivery technologies that try to enhance oncology drugs’ efficacy, safety, or both. ImmunoGen’s TAP technology has demonstrated time and time again it improves both safety and efficacy and makes cancer drugs work after the same drugs fail to work when used alone, i.e., not within ImmunoGen’s targeted monoclonal antibody designed armed vehicle.  More...

WHY A SELLOFF IN THE BEST OF THE BEST ONCOLOGY BIOTECH FIRMS?

  Wednesday, August 15, 2012

If the selloff of the best of the best small oncology biotech stocks was not a concerted, multiparty effort by influential groups, then what else could have caused it? The stocks devastated after the quarterly financial announcements are Incyte (INCY), ImmunoGen (IMGN) and Aveo (AVEO), Exelixis (EXEL) and to a lesser extent Seattle Genetics (SGEN). These firms received five-star ratings from top analysts, as they have programs and products that promise colossal growth. Their technologies and targeted products are perfect fits as essential building blocks of the strategy of future cancer management, i.e., the large-scale practice of personalized medicine. Some of them are also developing drugs that circumvent cancer resistance and increase the efficacy of other oncology drugs.    More...


Recent News_and_Comments


Archive


Tags